Clinical trials for Prostate cancer

148 currently recruiting clinical trials

Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT06581432 #2023-510429-14-00
HER2 Positive Locally Advanced Metastatic Metastatic Castration-resistant HER2 1 2 3 or more
Systemic Treatment-Naive
4 recruiting sites
Boehringer Ingelheim
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST #NCT06760819 #2024-517419-62-00
Stomach Oesogastric junction Esophagus Adenocarcinoma Intrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinoma Ampullary carcinoma Gastrointestinal stromal tumor Squamous cell carcinoma Other HER2 Positive Locally Advanced Metastatic Metastatic Castration-resistant HER2 1
Systemic Treatment-Naive
6 recruiting sites
Bayer
Phase 2 Prostate cancer #NCT06866938 #2024-512043-22-00
Adenocarcinoma Metastatic Castration-resistant PSMA PET Positive Chemotherapy Hormone therapy
Systemic Treatment-Naive
4 recruiting sites
Hospices Civils de Lyon
Phase 2 Prostate cancer #NCT05489211 #2023-509436-26-00
Metastatic Castration-resistant 1 2 3 or more
Antibody Drug Conjugates (ADC) Systemic Treatment-Naive Antibody Drug Conjugates (ADC)
2 recruiting sites
AstraZeneca
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT03767075 #2024-514238-19-00
Locally Advanced Metastatic Metastatic Castration-resistant EGFR FGFR MET 1 2 3 or more
Systemic Treatment-Naive
1 recruiting site
Institut d'oncologie du Vall d'Hebron
Phase 2 Prostate cancer #NCT06172478 #2023-507641-29-00
Adenocarcinoma Metastatic Castration-resistant 1 2 3 or more Chemotherapy Hormone therapy
Systemic Treatment-Naive
9 recruiting sites
Daiichi Sankyo
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT03175224 #2024-514542-37-00
Locally Advanced Metastatic MET 1 2 3 or more
BRAF EGFR KRAS G12C KRAS non G12C NTRK-1/2/3 RET ALK ROS-1 Systemic Treatment-Naive Targeted therapy
5 recruiting sites
Apollomics
Phase 2 Prostate cancer #NCT06582628 #2023-510536-37-00
Adenocarcinoma Metastatic Castration-resistant None
1 recruiting site
Fundacion Oncosur
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer #NCT05384626 #2024-514266-39-00
Locally Advanced Metastatic Metastatic Castration-resistant ALK 1 2 3 or more
AKT ATM BRAF BRCA 1/2 CDK12 CHEK 1/2 ESR FGFR HER2 HOXB13 KRAS G12C KRAS non G12C MET MSI/dMMR NRAS NTRK-1/2/3 PALB2 PIK3CA PTEN RET Systemic Treatment-Naive
4 recruiting sites
Nuvalent Inc.
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06653777 #2024-512729-10-00
Locally Advanced Metastatic Metastatic Castration-resistant FGFR 1 2 3 or more
Systemic Treatment-Naive
6 recruiting sites
UNICANCER